This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pryer, N. K. Articles by London, C. A. Search for Related Content PubMed PubMed Citation Articles by Pryer, N. K. Articles by London, C. A.

Proof of Target for SU11654

Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors

¹ SUGEN, Inc., South San Francisco, California, and
² School of Veterinary Medicine, University of California-Davis, Davis, California

Purpose: The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of its molecular target KIT in canine mast cell tumors (MCT) and correlate target inhibition with mutational status of the c-kit juxtamembrane domain and SU11654 plasma concentration.

Experimental Design: Tumor biopsies were obtained from dogs with advanced MCTs before and 8 h after administration of a single oral dose of SU11654, previously shown to be active in dogs with MCTs. Blood samples were taken to determine the plasma concentration of SU11654. Levels of phosphorylated KIT and ERK1/2 were assessed in tumor biopsies by Western blot. Tumors were analyzed by PCR for the presence or absence of an internal tandem duplication (ITD) in the juxtamembrane domain of c-kit.

Results: Fourteen dogs with advanced MCTs were enrolled in the study; 11 of these were evaluable for KIT target modulation (the remaining tumor specimens had inevaluable amounts of total KIT protein). Of these, eight MCTs showed reduced levels of phosphorylated KIT relative to total KIT after treatment with SU11654, compared with pretreatment biopsies. All four evaluable MCTs expressing ITD mutant c-kitshowed modulation of KIT phosphorylation, as did four of seven tumors expressing non-ITD c-kit. Phosphorylated ERK1/2 was modulated in seven tumors; this did not correlate with inhibition of KIT phosphorylation

Conclusion: SU11654 treatment at the efficacious dose results in inhibition of KIT phosphorylation in canine MCTs.

This article has been cited by other articles:

				C. A. London, P. B. Malpas, S. L. Wood-Follis, J. F. Boucher, A. W. Rusk, M. P. Rosenberg, C. J. Henry, K. L. Mitchener, M. K. Klein, J. G. Hintermeister, et al. Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision Clin. Cancer Res., June 1, 2009; 15(11): 3856 - 3865. [Abstract] [Full Text] [PDF]

				C. Khanna and I. Gordon Catching Cancer by the Tail: New Perspectives on the Use of Kinase Inhibitors Clin. Cancer Res., June 1, 2009; 15(11): 3645 - 3647. [Abstract] [Full Text] [PDF]

				J. D. Webster, V. Yuzbasiyan-Gurkan, R. A. Miller, J. B. Kaneene, and M. Kiupel Cellular Proliferation in Canine Cutaneous Mast Cell Tumors: Associations with c-KIT and Its Role in Prognostication Vet. Pathol., May 1, 2007; 44(3): 298 - 308. [Abstract] [Full Text] [PDF]

				J. M. Cherrington Taking Biological Targeted Agents into Clinical Trial Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 23 - 29. [Full Text] [PDF]